Neurochemical and neurobehavioral effects of ganstigmine (CHF2819), a novel acetylcholinesterase inhibitor, in rat prefrontal cortex: An in vivo study

Pharmacological Research

Volumn 56, Issue 4, 2007, Pages 288-294

  Trabace, Luigia ^a   Cassano, Tommaso ^a   Colaianna, Marilena ^a   Castrignanò, Silvia ^a   Giustino, Arcangela ^b   Amoroso, Salvatore ^c   Steardo, Luca ^d   Cuomo, Vincenzo ^d  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Ganstigmine; Prefrontal cortex; Rat

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DOPAMINE; GANSTIGMINE; NORADRENALIN; SCOPOLAMINE BROMIDE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN LEVEL; CONTROLLED STUDY; EXTRACELLULAR FLUID; IN VIVO STUDY; MALE; METABOLITE; NEUROCHEMISTRY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; WORKING MEMORY;

3,4-DIHYDROXYPHENYLACETIC ACID; ACETYLCHOLINE; ADMINISTRATION, ORAL; ALKALOIDS; ANALYSIS OF VARIANCE; ANIMALS; CARBAMATES; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; EXPLORATORY BEHAVIOR; EXTRACELLULAR SPACE; HOMOVANILLIC ACID; MALE; MEMORY; NOREPINEPHRINE; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SCOPOLAMINE; SEROTONIN;

EID: 34748825493     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.07.006     Document Type: Article

References (28)

1. Becker R.E., Moriearty P., Unni P., and Vicari S. Cholinesterase inhibitors as therapy in Alzheimer's disease: benefit to risk considerations in clinical application. In: Becker R., and Giacobini E. (Eds). Alzheimer's disease: from molecular biology to therapy (1997), Birkhauser, Boston 257-266
2. Trabace L., Cassano T., Loverre A., Steardo L., and Cuomo V. CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor. CNS Drug Rev 8 1 (2002) 53-69
3. Pietra C., Villetti G., Bolzoni P.T., Delcanale M., Amari G., Caruso P., et al. Cholinesterase inhibitory activity of new geneserine derivatives. In: Iqbal K., Swaab D.F., Winblad B., and Wisniewski H.M. (Eds). Alzheimer's disease and related disorders (1999), John Wiley & Sons Ltd. 689-696
4. Trabace L., Cassano T., Steardo L., Pietra C., Villetti G., Kendrick K., et al. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther 294 1 (2000) 187-194
5. Trabace L., Cassano T., Cagiano R., Tattoli M., Pietra C., Steardo L., et al. Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels. Brain Res 910 (2001) 182-186
6. Masliah E., and Licastro F. Neuronal and synaptic loss, reactive gliosis, microglial response and induction of the complement cascade in Alzheimer'disease. In: Clark C.M., and Trojanowski J.Q. (Eds). Neurodegenerative dementias: clinical features and pathological mechanisms (2000), McGraw-Hill, New York 131-146
7. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66 (1999) 137-147
8. Memo M., Missale C., Trivelli L., and Spano P.F. Acute scopolamine treatment decreases dopamine metabolism in rat hippocampus and frontal cortex. Eur J Pharmacol 149 (1988) 367-370
9. Robinson T.N., de Souza R.J., Cross A.J., and Green A.R. The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms. Br J Pharmacol 98 (1989) 1127-1136
10. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1982), Academic Press, New York
11. Trabace L., and Kendrick K.M. Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. J Neurochem 75 4 (2000) 1664-1674
12. Kendric K., Guevara-Guzman K.M., de la Riva R., Christensen C., Ostergaard J., and Emson K.P. NMDA and Kainate-evoked release of nitric oxide and classical transmitters in the rat striatum: in vivo evidence that nitric oxide may play a neuroprotective role. Eur J Neurosci 8 (1996) 2619-2634
13. Ennaceur A., and Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1. Behavioral data. Behav Brain Res 31 1 (1988) 47-59
14. Messamore E., Ogane N., and Giacobini E. Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum. Neuropharmacology 32 (1993) 291-296
15. de Boer P., Westerink B.H., and Horn A.S. The effect of acetylcholinesterase inhibition on the release of acetylcholine from the striatum in vivo: interaction with autoreceptor responses. Neurosci Lett 116 (1990) 357-360
16. Scali C., Giovannini M.G., Prosperi C., Bartolini L., and Pepeu G. Tacrine administration enhances extracellular acetylcholine in vivo and restores the cognitive impairment in aged rats. Pharmacol Res 36 (1997) 463-469
17. Giovannini M.G., Scali C., Bartolini L., Schmidt B.H., and Pepeu G. Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F334 rats. Eur J Pharmacol 354 (1998) 17-24
18. Vizi E.S., and Kiss J.P. Neurochemistry and pharmacology of the major hippocampal transmitter system: synaptic and nonsynaptic interactions. Hippocampus 8 (1998) 566-607
19. Bianchi C., Tanganelli S., Marzola G., and Beani L. GABA-induced changes in acetylcholine release from slices of guinea-pig brain. Naunyn-Schmiedeberg's Arch Pharmacol 318 (1982) 253-258
20. Decker M.W., and McGaugh J.L. The role of interactions between cholinergic systems and other neuromodulatory systems in learning and memory. Synapse 7 (1991) 151-168
21. Howerton T.C., Murphy M.R., Miller S.A., and Hartgraves S.L. Differential sensitivity of CNS regions to acetylcholinesterase inhibition following chronic low-dose soman treatment in the rat. Psychopharmacology (Berl) 105 3 (1991) 400-406
22. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E. (Ed). Cholinesterases and cholinesterase inhibitors (2000), Martin Dunitz, London 181-226
23. Kaufer D., Friedman A., Scidman S., and Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 393 (1998) 373-377
24. Hinz V.C., Kolb J., and Schmidt B.H. Effects of subchronic administration of metrifonate on cholinergic neurotransmission in rats. Neurochem Res 23 7 (1998) 931-938
25. Giustino A., Cagiano R., Carratù M.R., Cassano T., Tattoli M., and Cuomo V. Prenatal exposure to low concentrations of carbon monoxide alters habituation and non-spatial working memory in rat offspring. Brain Res 844 (1999) 201-205
26. Bartolini L., Casamenti F., and Pepeu G. Aniracetam restores object recognition impaired by age, scopolamine and nucleus basalis lesions. Pharmacol Biochem Behav 53 (1996) 277-283
27. Ennaceur A., and Meliani K. Effects of physostigmine and scopolamine on rat's performances in object-recognition and radial maze tests. Psychopharmacology 109 (1992) 321-330
28. Acquas E., Wison C., and Fibiger H.C. Conditioned and unconditioned stimuli increase frontal cortical and hippocampal acetylcholine release: effects of novelty, habituation, and fear. J Neurosci 16 (1996) 3088-3096